Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Losartan - Bristol-Myers Squibb/Merck & Co

Next Previous
Drug Profile

Losartan - Bristol-Myers Squibb/Merck & Co

Alternative Names: Cozaar; Cozaarex; DUP 753; Lortaan; Losaprex; Losartan potassium; MK 954; Neo Lotan; Nu-Lotan; Oscaar

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme; Neopharmed Gentili; S Riesel; sigma-tau SpA
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Heart failure; Hypertension

Most Recent Events

  • 11 Apr 2021 Discontinued - Phase-III for Hypertension (In children, In infants) in USA, Romania, Spain, Lithuania, United Kingdom, Peru, Mexico, Guatemala, Colombia, Chile, Brazil, Philippines, Russia, Norway, India, Argentina, Hungary (PO)
  • 08 Jun 2012 Merck & Co. completes enrolment in its Phase-III trial for Hypertension (in children and infants aged 6 months to 6 years) in USA, European Union, Latin America, India, Norway, Philippines and Russia (NCT00756938)
  • 26 Jan 2012 Generic equivalent available in Canada for Hypertension & Diabetic nephropathies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top